focus -WSS

focus

author：comprehensive 2025-09-28 02:31:46 - browse：136

Alex Hogan/STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods.

This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot. After a volatile 2023 that saw biotech stocks hit five-year lows in the fall, the sector had a bull run in the final weeks of the year, spurred by some high-dollar merger agreements and a prevailing sense that the macroeconomic winds were finally shifting in biotech’s direction.

Meanwhile, companies selling digital health services like telemedicine, health plans for virtual care, and AI tools for payers face a crucial year as they scramble to make good on profitability projections. Those companies, along with the country’s most powerful health systems, are seriously exploring AI, even ChatGPT, to help them meet financial milestones.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Supreme Court rules employers must be more accommodating of religious observance

focus

WSS

Tuskegee Airman Raymond Cassagnol dies at 102

Synthetic human embryos? Researchers say term is overblown

Was Amgen transparent enough on FDA's concern on cancer drug?

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Physician executives need more than on

Thousands protest in Iraq for a second day over burning of Quran in Sweden

knowledge

focus

explore

Hepatitis C has a cure — but many Americans still lack access to it

Synthetic human embryos? Researchers say term is overblown

Medical records are filled with copy

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Novavax promises a turnaround & Lilly roils the obesity market

Bristol 'take

How to save PrEP access — and even expand it

A Q&A with the global head of Boehringer Ingelheim's innovation unit

23andMe had bad news about my health. I wish a person had delivered it

Synthetic human embryos? Researchers say term is overblown

knowledge

3 questions for the future of Biden's cancer moonshot

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Was Amgen transparent enough on FDA's concern on cancer drug?

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Illumina to lay off 10% of research and development team

Bill would stop addiction treatment from triggering child abuse inquiry

hotspot

focus

focus

entertainment